Full-Time
Develops pridopidine treatments for neurodegenerative diseases
No salary listed
Boston, MA, USA
Remote
Fully remote US role; up to 70% travel (domestic); flexible schedule across NA time zones.
PharmD, PhD, MD
See people who can refer or advise you
Prilenia develops and commercializes medicines for brain diseases. It focuses on creating treatments for neurodegenerative conditions (like Huntington’s disease and ALS) and neurodevelopmental disorders. Its main candidate is pridopidine, a drug studied to help brain cells by activating the sigma-1 receptor (S1R), which researchers believe can help restore brain pathways impaired in these diseases. The product works by engaging S1R to support neuronal function, with the goal of slowing symptoms or progression once approved. Prilenia aims to stand out by its specific focus on S1R biology, building a pipeline of potential therapies, and bringing these treatments to patients through regulatory approval and commercialization. The company’s goal is to provide validated therapies that address urgent needs for patients and families affected by neurodegenerative and neurodevelopmental disorders, while growing its team and expanding its pipeline for future medicines.
Company Size
51-200
Company Stage
Series B
Total Funding
$115.5M
Headquarters
Herzliya, Israel
Founded
2018
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Flexible Work Hours
Wellness Program
Mental Health Support
Conference Attendance Budget
Family Planning Benefits
Fertility Treatment Support
Stock Options
401(k) Retirement Plan
401(k) Company Match
Prilenia Therapeutics, a biopharmaceutical company focused on Huntington's disease and Amyotrophic Lateral Sclerosis treatments, has appointed Dr Elisabeth Leiderman as Chief Financial Officer. Leiderman brings over 20 years of finance and corporate development experience in life sciences. She has previously served as CFO at multiple biotech companies including Dewpoint, Atsena and Decibel, and currently sits on the board of Autolus Therapeutics. She also held senior investment banking positions at UBS, Credit Suisse and Nomura. The appointment comes as Prilenia embarks on two Phase 3 studies for its drug pridopidine in HD and ALS. Leiderman will focus on managing the company's financial runway through Phase 3 completion whilst preparing for potential commercialisation.
NAARDEN, Netherlands & WALTHAM, Mass. - (BUSINESS WIRE) - Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets.
Prilenia appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer.
NAARDEN, Netherlands WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, today announced the presentation of the latest research from the pridopidine Huntington disease (HD) and amyotrophic lateral sclerosis (ALS) programs at the American Academy of Neurology (AAN) Annual Congress, in Denver, Colorado, April 13-18. “Pridopidine is now in pre-registration phase in HD, with a first submission planned Mid 2024i, and is also set to commence a global Phase 3 study in ALS later this year. We are making significant strides forward and this is reflected by presentation of the data at one of the most important medical congresses in the field of Neurology,” said Jina Swarz, MD. Ph.D., the recently appointed Chief Medical Officer of Prilenia. “Pridopidine is one of the most advanced investigational new drugs in HD and ALS and has shown consistent treatment benefits across independent measures that are important to patients and families. The presented data advances knowledge in the field, providing important learnings for both clinical practice and for the design of our programs going forward
NAARDEN, Netherlands WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, announced its plan to submit a Marketing Authorization Application (MAA) for pridopidine for the treatment of Huntington’s disease (HD) to the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). This decision follows positive pre-submission meetings with regulatory authorities in the European Union. Submission is planned for mid-2024. “Pridopidine demonstrates consistent treatment benefits across independent measures that are important to patients and families. These measures include day-to-day function, cognition, motor and clinical progression in people living with HD. The benefits are clearly evident in those with HD who are not taking anti-dopaminergic medications (ADM),” said Dr